FDA: Evusheld may lack efficacy against upcoming COVID-19 subvariants

Evusheld demonstrates reduced protection against the omicron subvariant BA.4.6, resulting in an increased risk for infection in those exposed to that COVID-19 strain, according to an updated FDA fact sheet.

In the revised fact sheet, the FDA warned that providers should be aware of an increased risk for developing COVID-19 when exposed to certain COVID-19 variants that are not neutralized by tixagevimab packaged with cilgavimab (Evusheld, AstraZeneca).
Read the full story in Healio.